 |
|
|
| |
Bemnifosbuvir and ruzasvir administered as a fixed-dose combination has low potential to inhibit P-gp, BCRP or OATP1B1/3 mediated transport
|
| |
| |
EASL 2026 May 26-30 Barcelona
Xiao-Jian Zhou,1 Gaetano Morelli,2 Maureen Montrond,1 Keith Pietropaolo,1 Bruce Belanger,1 Shannan Lynch,1 Dayle James,1 Maria Arantxa Horga,1 Janet Hammond1
1. Atea Pharmaceuticals, Inc., Boston, USA; 2. Altasciences, Montreal, Canada.
|
| |
|
|
|
|
|
